Lupin Q4 net up 48%; beats estimates

Reuters Mumbai | Updated on January 20, 2018 Published on May 19, 2016

Lupin Ltd, India's third-largest drugmaker, has reported a 48 per cent rise in quarterly net profit, outpacing analysts’ estimates mainly due to higher drug sales in its largest market, the United States.

Net profit for the January-March quarter was Rs 807 crore ($119.91 million), compared with Rs 547 crore a year earlier. Analysts polled by Thomson Reuters expected an average profit of Rs 678 crore.

Lupin has benefitted in recent months from a steady pace of new drug approvals in the United States at a time when most of its peers have been facing delays in getting approvals due to regulatory troubles.

Published on May 19, 2016
This article is closed for comments.
Please Email the Editor